INMED PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
INMED PHARMACEUTICALS INC. (INM) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.28% for the 12-month period ending 2025-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-09-09
- INMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-09-30 was 3.59%.
- INMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.74%, a 219.66% increase from fiscal 2022.
- INMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 1.17%, a 333.33% increase from fiscal 2021.
- INMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2021 was 0.27%, a 82.12% decline from fiscal 2020.
- INMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2020 was 1.51%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2025-06-30 | 4.28% S-4/A · filed 2026-09-09 | |||
| 2025-03-31 | 4.21% 10-Q · filed 2025-05-12 | |||
| 2024-12-31 | 4.21% 10-Q · filed 2025-02-12 | |||
| 2023-12-31 | 3.95% 10-Q · filed 2025-02-12 | |||
| 2023-06-30 | 3.74% 10-K · filed 2023-09-29 | |||
| 2023-03-31 | 3.74% 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | 3.74% 10-Q · filed 2023-02-17 | |||
| 2022-09-30 | 3.59% 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | 1.17% 10-K · filed 2023-09-29 | |||
| 2022-03-31 | 1.14% 10-Q · filed 2022-05-13 | |||
| 2021-12-31 | 1.11% 10-Q · filed 2022-02-14 | |||
| 2021-06-30 | 0.27% 10-K · filed 2022-09-23 | |||
| 2021-03-31 | 0.25% 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | 0.25% 10-Q · filed 2021-02-11 | |||
| 2020-06-30 | 1.51% 10-K · filed 2021-09-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |